|
The
following potentially dilutive securities were excluded from the calculation of diluted net loss per share because the effects were anti-dilutive
based on the application of the treasury stock method and because the Company incurred net losses during the period:
SCHEDULE
OF ANTI DILUTIVE SECURITIES
| |
|
2022 |
|
|
2021 |
|
|
2022 |
|
|
2021 |
|
| |
|
For
the Nine Months Ended September 30, |
|
|
For
the Three Months Ended September 30, |
|
| |
|
2022 |
|
|
2021 |
|
|
2022 |
|
|
2021 |
|
| Convertible
notes payable |
|
|
9,386,463 |
|
|
|
5,532,796 |
|
|
|
9,386,463 |
|
|
|
5,532,796 |
|
| Warrants
to purchase shares of common stock |
|
|
11,841,160 |
|
|
|
7,222,558 |
|
|
|
11,841,160 |
|
|
|
7,222,558 |
|
| Total
potentially dilutive shares |
|
|
21,227,623 |
|
|
|
12,755,354 |
|
|
|
21,227,623 |
|
|
|
12,755,354 |
|
|